Study details
Enrolling now
EXPRESS+ Trial
University of California, Los Angeles
NCT IDNCT05558345ClinicalTrials.gov data as of Apr 2026
Target enrollment
55
Study length
about 3.6 years
Ages
18–45
Sex
Male only
Locations
1 site in CA
About this study
This trial is testing whether changes in stress markers happen during meth treatment. It's for people with HIV/AIDS and methamphetamine use disorder, who are male. It lasts 1307 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Contingency Management
Primary goalChange in Inflammatory and Type I IFN Gene Expression over 12 weeks
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change in Inflammatory and Type I IFN Gene Expression over 12 weeks
Body systems
Psychiatry / Mental Health, Immune, Infectious